U
NDERSTANDING THE ACTION of antipsychotic drugs has been at the heart of 5 decades of schizophrenia research. 1, 2 The clinical efficacy and adverse effects of antipsychotics have been consistently related to the level of in vivo occupancy at the D 2 receptors. [3] [4] [5] [6] [7] [8] [9] Previous studies proposed that the occupancy required for clinical efficacy is in the range of 60%, while the occurrence of adverse effects has been observed at higher than 80% occupancy. [3] [4] [5] [6] [7] [8] [9] Allthesestudieshavebeenperformed with positron emission tomography (PET) or single-photon emission tomography radioligands that are antagonists for the dopamineD 2 /D 3 receptors:carbon11-labeled raclopride ([ The high-affinity state of the D 2 receptor is believed to be the functionally important one, as it mediates the activation of the second-messenger cascade on the postsynaptic membrane after the endogenous agonist has bound to the receptor. 13, 14 What makes the high-affinity state of the D 2 receptors particularly interesting is a series of experiments that have shown an increase in the number of D 2 receptors in the high-affinity state in several animal models of psychosis 15 and after long-term antipsychotic exposure, 15, 16 suggesting that the highaffinity state of the D 2 receptor is involved in the illness and its treatment. While these 2 states have been convincingly demonstrated for the D 2 receptor, the existence of the G-protein coupled and uncoupled states of the D 3 receptors is controversial [17] [18] [19] because of the inability of the G-protein analogs (eg, GppNHp) to shift it from the high-to the low-affinity state. 20 Since all previous PET imaging studies have used antagonist radioligands, which do not distinguish between the high-and low-affinity stages of the receptors, it remains unknown how antipsychotics bind to these 2 states in vivo.
Recently, our group has developed carbon 11-labeled (ϩ)-4-propyl-9-hydroxynaphthoxazine ([ 11 C]-(ϩ)-PHNO), a D 2 /D 3 receptor agonist radiotracer for use in humans. 21 [
11 C]-(ϩ)-PHNO binds with nanomolar affinity to D 2 and D 3 receptors, allowing for a prominent signal from the striatum, globus pallidus (GP), and substantia nigra. 18, 21, 22 Because [ 11 C]-(ϩ)-PHNO is an agonist radiotracer, it binds preferentially to the high-affinity state of the receptor. 13, 14 In addition, [ 11 C]-(ϩ)-PHNO shows more than 10-fold higher in vitro affinity for the D 3 receptor than the D 2 receptor. 18, 23 This preferential in vitro binding to the D 3 receptor has been confirmed ex vivo in rodents 24 and in vivo in nonhuman primates and humans 25, 26 in the D 3 receptorrich regions like the GP, where D 3 receptor binding is thought to account for about 80% of the [ 11 C]-(ϩ)-PHNO signal. This is in contrast to the signal in the dorsal striatum (caudate and putamen), which is 10% to 40% in the D 3 receptor. 27, 28 Consequently, the GP can be used as a preferential D 3 receptor binding region and the dorsal striatum, as a preferential D 2 receptor region. 21, [24] [25] [26] [28] [29] [30] Therefore, the concomitant use of [ C]raclopride. While the 2 radiotracers gave relatively similar occupancies in the caudate and putamen, they showed widely divergent results in the GP, where no occupancy was found with [
11 C]-(ϩ)-PHNO. To understand this discrepancy further, and to confirm the D 3 receptor of [ 11 C]-(ϩ)-PHNO signal in the GP, we challenged a second set of patients with a single dose of pramipexole dihydrochloride, a preferential D 3 receptor agonist, to obtain displacement (reduction) of the increased binding in the GP and corroborate the D 3 receptor nature of this signal.
METHODS

CLINICAL SAMPLE
This study was approved by the local research ethics board and by Health Canada. Forty-six subjects were included in the following groups: (1) patients receiving long-term antipsychotic treatment (n = 20: clozapine, n = 7; olanzapine, n = 7; and risperidone, n=6); (2) patients receiving long-term risperidone treatment studied before and after a pramipexole-placebo challenge (n=3); and (3) healthy controls (n=23).
The participants provided written informed consent after the study procedures and risks were explained. They were excluded if they had a current diagnosis of substance abuse or dependence at screening, had a positive result in urine drug screen at enrollment or before any of the PET scans, had a history of clinically significant physical illness, were pregnant or lactating at screening, or had positive urine pregnancy test results before PET scans or metal implants that would preclude magnetic resonance imaging.
The patients were evaluated before each PET scan with the Clinical Global Impression scale, Positive and Negative Syndrome Scale, Simpson-Angus Scale, and Barnes Akathisia Scale in addition to the variables recorded during the initial assessment that are detailed in Table 1 .
STUDY GROUPS
Antipsychotic-Treated Patients
Twenty patients with either schizophrenia, schizophreniform, or schizoaffective disorder corroborated with the MiniInternational Neuropsychiatric Interview Plus 31 underwent PET scanning twice on separate days, 1 day apart. The age range for inclusion was 18 to 50 years. The patients were receiving clozapine, olanzapine, or risperidone as antipsychotic monotherapy at a steady clinical dose for more than 4 weeks without use of depot antipsychotic drugs during the previous 6 months. The first scan was performed with [ 11 C]raclopride. The PET scans were acquired at the expected serum peak time of the last antipsychotic dose (2, 6, and 3 hours for risperidone, olanzapine, and clozapine, respectively). Blood samples for the quantification of antipsychotic and prolactin plasma levels were obtained before and after each PET scan. The reported plasma levels were the mean of both measures.
Patients With Pramipexole Challenge
Three patients treated long-term with risperidone and with similar characteristics to the antipsychotic-treated patients were scanned twice with [ 11 C]-(ϩ)-PHNO at least 2 days apart. The PET scans were timed 12 hours after the last oral dose of risperidone. Two hours before each PET scan, the subjects received a single oral dose of 0.5 mg of pramipexole dihydrochloride or placebo. for inclusion was 19 to 50 years. Subjects with any medical or neurological conditions or with Axis I psychiatric diagnoses were excluded from the study. Similarly, subjects with substance abuse other than nicotine within 6 months prior to their baseline visit were not included. Participants were asked to consume no more than their usual amount of coffee (and if smokers, cigarettes) the day of PET examinations and to abstain from alcohol intake 24 hours before PET scans. Standard urine tests for psychotropic substances were performed at inclusion and immediately before each PET scan. Pregnancy was excluded using serum analysis at inclusion and urine pregnancy tests before each scan. 
Healthy Controls
PET IMAGING
Studies were performed using a high-resolution brain PET camera system (HRRT; Siemens Molecular Imaging, Knoxville, Tennessee), described in detail elsewhere. 25, 34, 35 After being placed on the scanning bed, a mean (SD) of 330 (55) MBq (to convert to curies, divide by 37 000) (range, 200-407 MBq) with a specific activity of 39 000 (11 360) MBq/µmol (range, 17 940-64 000 MBq/µmol) of [ 11 C]-(ϩ)-PHNO was injected as a bolus followed by a flush with 2 mL of saline into an intravenous catheter placed in an antecubital vein. Scanning data were acquired for 90 minutes after the injection. Once scanning was completed, the data were reframed into 30 frames 
MAGNETIC RESONANCE IMAGING
Subjects underwent a proton density image (echo time=17 milliseconds; repetition time=6000 milliseconds; field of view=22 cm, 2-dimensional, 256ϫ256; slice thickness, 2 mm; number of excitations=2), acquired on a 1.5-T Signa scanner (General Electric Medical Systems, Milwaukee, Wisconsin). These images were used for the analysis of the PET scans.
IMAGE ANALYSIS
The procedure for the analysis of the [ 25, 34, 35 The quantitative estimate of binding was estimated using the Simplified Reference Tissue Method (SRTM), 36 with the cerebellar cortex as the reference region. This method has been validated to reliably estimate the nondisplaceable binding potential (BP ND ), which compares the concentration of radioligand in the receptor-rich region with the receptor-free region, 37 for both [ 11 C]raclopride 38 and [ 11 C]-(ϩ)-PHNO. 30 In addition, to assure the robustness of our findings, we analyzed the data using 3 additional methods: the interval ratio, 39 the multilinear reference tissue model (MRTM), and the multilinear reference tissue model 2 (MRTM2). 40 We included the interval method as an intuitive approach based on the shape of the time activity curves, and the MRTM and MRTM2 were included because, in contrast to SRTM, they are linearized reference tissue methods that are resistant to noise. 40 The times for the interval method were caudate and putamen, 840 to 1800 seconds; ventral striatum, 900 to 3000 seconds; and GP, 2100 to 4200 seconds. These intervals showed the lowest variation in our controls (Ͻ5%). The BP ND was estimated using PMOD v2.7 software (PMOD Technologies Ltd, Zurich, Switzerland). In addition, PMOD provided for SRTM, MRTM, and MRTM2 the coefficients of variation of the standard error of the parameter identifiability (called "standard error" of the compartmental fit).
Parametric voxel-wise BP ND maps from the dynamic images in native space were generated according to the method of Gunn et al, 41 with the cerebellum as the reference region, and as implemented in PMOD v2.7 software. The BP ND map images were spatially normalized into Montreal Neurological Institute brain space by nearest neighbor interpolation and with a voxel size fixed at 2 ϫ 2 ϫ 2 mm using the SPM2 software. 42 The normalized images were smoothed with a gaussian filter in each coordinate direction, with a kernel of 4 mm.
Receptor occupancy was defined as the percentage of reduction of the BP ND from a baseline state to the treated state. To calculate receptor occupancy, a measure of baseline BP ND in the drug-free (untreated) state was necessary. Since we could not obtain baseline measures of D 2 receptors for the antipsychotic-treated patients within our current design, we used estimates of BP ND from age-and sex-matched controls derived from healthy volunteers, using the slope and intercept for each region of interest obtained from the linear regression of BP ND and age for each sex (eTable 1, http:// www.archgenpsychiatry.com). Also, as an additional analysis, the data from drug-free patients 43 were pooled with the healthy controls data to estimate the percentage of receptor occupancy and did not modify the occupancies as estimated with healthy controls (analysis presented). The occupancies reported in the results correspond to those obtained with SRTM unless otherwise indicated. The occupancies were estimated with the following formula:
The percentage of BP ND change after the pramipexole challenge was estimated considering as baseline the PET scan with placebo.
Nonlinear regression analysis was applied to correlate the plasma level of clozapine, olanzapine, or risperidone with the respective occupancy (SRTM). The data were fitted to a rectangular hyperbola (1-site binding model) described by the equation:
where ED 50 represents the plasma level of antipsychotics resulting in 50% receptor occupancy and X corresponds to the ceiling receptor's occupancy. In the models, X was fixed to 100 and ED 50 Ͼ0.
STATISTICAL ANALYSIS
The analysis was made using SPSS (version 12.0; SPSS, Chicago, Illinois). Variables were presented as mean (standard deviation). Demographic and clinical characteristics were compared between patients and controls by using the MannWhitney U test for categorical data and independent-sample t tests for continuous data. Analysis of variance with a post hoc paired t test was performed to compare the clinical variables and plasma levels between PET scan days and to compare the occupancies between radiotracers ([ 
RESULTS
LONG-TERM-TREATED PATIENTS IN COMPARISON WITH HEALTHY CONTROLS
The patients treated long-term with olanzapine, clozapine, or risperidone had mean (SD) occupancies with C]-(ϩ)-PHNO, this was 17% (34%) (t 19 =−6.04; PϽ.001), which is between that observed in the dorsal striatum (caudate and putamen) and the GP ( Table 2) (Figures 1, 2, and 3) . To confirm the reliability of this finding across different analytic methods, the [ 11 C]-(ϩ)-PHNO occupancies were obtained using BP ND derived by the interval ratio, MRTM, and MRTM2 methods. The results with all the methods showed higher BP ND in patients taking antipsychotics than controls in the GP (eTable 2). The clinical variables and the serum plasma level of the antipsychotics and metabolites were not different between the [ (Figure 4) .
DISPLACEMENT OF ELEVATED BINDING BY THE PRAMIPEXOLE CHALLENGE
COMMENT
To our knowledge, this is the first study to compare the antipsychotic occupancies as measured by an agonist and an antagonist radiotracer and provides the first evidence of the effects of antipsychotics on the low-and the high-affinity states of the dopamine receptors, as well as providing insights into the differential effect of the drugs on D 3 The major new finding in our study is that the [ 11 C]-(ϩ)-PHNO binding in the GP and ventral striatum is not blocked by long-term antipsychotic exposure in patients with schizophrenia. Our group recently reported that the [ 11 C]-(ϩ)-PHNO binding is not different between drug-free patients with schizophrenia and age-and sex-matched healthy controls in any brain region. 43 What makes the D 3 receptors particularly interesting is their preferential distribution in the limbic regions and their rigid configuration in high-affinity states for dopamine. 17, 18 This configuration may imply that in vivo this receptor is occupied by endogenous dopamine for longer periods, suggesting a special role for D 3 receptors in mediating tonic (background) dopamine transmission. 44 As a result of this functional distribution and sensitivity to background dopamine levels, small changes in their number may have important functional implications, especially for neuropsychiatry disorders. binding may be explained by changes induced by antipsychotics on a variety of intracellular mechanisms leading to an increase in B max . [45] [46] [47] However, the preclinical data on this matter are equivocal. Some studies have reported an increase in D 3 receptor messenger RNA, [48] [49] [50] but other studies have found no change in D 3 receptor messenger RNA or D 3 receptor labeling. [51] [52] [53] [54] [55] Additionally, a postmortem study 54 in patients with schizophrenia treated long-term did not find any difference in the total number and affinity (dissociation constant) of D 3 receptors. At present, both an increase in the B max or K dЈ remain possible and only further experimentation will choose between them.
The occupancies in the D 2 receptor-rich areas (caudate and putamen) were always lower with [
11 C]-(ϩ)-PHNO (Table 2) . A simple explanation for the difference in occupancy could be that antipsychotics show less affinity for the high-vs the low-affinity states of the D 2 receptors, and since [ 56 However, this higher sensitivity was not replicated in an ex vivo dissection study in awake rodents, 57 though it is suggested by the study in awake and healthy humans. 35 The cause of this discrepancy between studies is still elusive, though the cat and human studies suggest that [ The explanation of less affinity for the high-vs the lowaffinity states seems to be unlikely, as studies in vitro have generally shown that the current antipsychotics have similar affinities for the high-and the low-affinity states. 58 In addition, an ex vivo study in rodents using [ 11 C]-(ϩ)-PHNO and [
3 H]raclopride confirmed the in vitro results, indicating that affinities (ED 50 ) for haloperidol and clozapine are the same with both radiotracers. 57 On the other hand, the more likely explanation is that the lower [ tive D 3 vs D 2 receptor density as observed in humans in vitro and in nonhuman primates is caudate less than putamen less than ventral striatum less than GP. 28, [59] [60] [61] 30 they do not reflect absolute parameterssomething we discuss further later. Nonetheless, on comparing these 3 possibilities, we favor the differential D 3 vs D 2 receptor as the preferred explanation as it explains not only the finding in the dorsal striatum, but the differentials in the other regions and is consistent with our main explanation for the GP.
Our study has several limitations but none that we think detract from the main conclusion herein. Since we did not have data on the drug-free state of our antipsychotic-treated patients, we had to derive occupancy levels by reference to a control population. While less than ideal, this is the most common approach in the literature, 62 and since we have recently shown that there are no differences between healthy controls and drug-free patients with schizophrenia, 43 it is unlikely to have biased our results. Another limitation is that the smoking status of the participants was not recorded. This limitation may be important in light of the effect of cigarette consumption, craving, and its mood or hedonic effect on the dopamine system [63] [64] [65] and that patients with schizophrenia are more likely to be smokers than the general population. 66 However, the overall effect of smoking or nicotine exposure on the BP ND is null or small (about 10% 11 C]raclopride. To our knowledge, this effect has never been explored with an agonist radiotracer.
The lack of arterial samples to perform a full kinetic analysis may also be a limitation of our study. A full kinetic analysis would allow direct estimation of the BP in the regions of interest without the potential bias induced by specific binding in the reference region and/or by changes in the kinetics of the signal of interest. However, it is of some reassurance to know that in the current study the cerebellar uptake values in patients and controls were not different ( Figure 3 ) (F 1,41 =0.29; P=.59). The SRTM approach to estimate BP ND with the cerebellum as a reference has a good correlation with the BP as estimated with a full kinetic analysis and it was validated in unmedicated controls for both radiotracers. 30, 38 This approach has been used repeatedly with reliable results with [ 11 C]raclopride in patients with schizophrenia taking antipsychotics. [3] [4] [5] [6] [7] 62 However, to our knowledge, the current study is the first with [
11 C]-(ϩ)-PHNO in patients taking antipsychotics and some limitations should be considered. To examine the dependence of these findings on any one method, we additionally estimated the BP ND with the interval ratio, MRTM, and MRTM2 methods. Across methods, the BP ND in the GP of patients treated long-term was always higher than controls (though the extent of the increase varied, 17%, 42%, and 41%, respectively) (eTable 2), even with the MRTM and MRTM2 methods, which showed lower coefficients of variance (eTable 4). However, the visual inspection of the time activity curves from the GP (Figure 3) suggests that while the initial part of the curve is reduced compared with controls (probably secondary to D 2 receptor block), the latest part (likely D 3 receptor related) is similar to controls. These effects result in a flat curve during the 90 minutes of scanning time, which provides the kinetic model with limited information about the off rate (k4) to properly estimate k3/k4.
An increase of the scanning time, to obtain enough offrate data, would overcome this limitation in kinetic modeling. However, the short half-life of 11 C would provide noisy data after 90 minutes and the agonist property of [ We used pramipexole to displace the signal in the D 3 receptor-rich areas of the patients treated long-term. Pramipexole is an agonist with an approximately 10-fold preference for D 3 receptors over D 2 receptors. 19, 67, 68 We were aware of the limited D 3 receptor:D 2 receptor selectivity of pramipexole, but it was the only medication with a high D 3 receptor selectivity that was available for us to use in patients. In addition, in vitro studies suggested that the doses ]-(ϩ)-PHNO) from a patient with schizophrenia treated long-term with risperidone (6 mg/d) and a sex-and age-matched healthy control. The images illustrate a decrease of the BP ND in the globus pallidus, ventral striatum, and substantia nigra (S. nigra) after a pramipexole dihydrochloride dose, without a reliable change in the dorsal striatum (caudate). The BP ND maps are overlaid on a T1-weighted magnetic resonance imaging template in Montreal Neurological Institute space and showed in axial projection.
(REPRINTED) ARCH GEN PSYCHIATRY/ VOL 66 (NO. 6), JUNE 2009administered to our patients were still in the D 3 receptor selectivity range 19, 67, 68 and this was confirmed post hoc in our study by the selective displacement showed in the GP and not in the dorsal striatum. As better and more selective D 3 receptor agents become available, it may become possible to definitively confirm what we propose herein. Finally, the patients were cross-sectionally chosen to meet the inclusion criteria of this study based on the drug that they were receiving, and their treatment was not prospectively controlled. This was not necessary for the current study and, hence, was not done. While confirming the results with 3 different antipsychotics and 4 modeling methods makes us confident of our finding, the clinical implications of this unblocked [ 11 C]-(ϩ)-PHNO signal remain to be elucidated.
To our knowledge, our study provides the first in vivo evidence for the effect of antipsychotics on the D 3 receptor and suggests that long-term antipsychotic treatment does not decrease [ 
